Michael J. Landine - Feb 18, 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
SVP, Corp Dev., Alkermes, Inc.
Signature
/s/ Jeffrey Geary, attorney-in-fact for Michael J. Landine
Stock symbol
ALKS
Transactions as of
Feb 18, 2024
Transactions value $
$387,239
Form type
4
Date filed
2/21/2024, 05:37 PM
Previous filing
Feb 12, 2024
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +4.45K +1.66% 273K Feb 18, 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability -$42.1K -1.31K -0.48% $32.18 272K Feb 18, 2024 Direct
transaction ALKS Ordinary Shares Options Exercise +5.46K +2.01% 277K Feb 20, 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability -$48.8K -1.61K -0.58% $30.39 276K Feb 20, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Employee Stock Option (Right to Buy) Other $46.2K +999 +2% $46.24 51K Nov 17, 2023 Ordinary Shares 999 $46.24 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $61.4K +879 +2% $69.83 44.9K Nov 17, 2023 Ordinary Shares 879 $69.83 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $48.1K +1.52K +2% $31.64 77.5K Nov 17, 2023 Ordinary Shares 1.52K $31.64 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $53.4K +999 +2% $53.50 51K Nov 17, 2023 Ordinary Shares 999 $53.50 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $71.8K +1.09K +2% $65.94 55.6K Nov 17, 2023 Ordinary Shares 1.09K $65.94 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $57.8K +1.81K +2% $31.93 92.4K Nov 17, 2023 Ordinary Shares 1.81K $31.93 Direct F2, F3
transaction ALKS Employee Stock Option (Right to Buy) Other $35.9K +1.79K +2% $20.03 91.3K Nov 17, 2023 Ordinary Shares 1.79K $20.03 Direct F2, F4
transaction ALKS Restricted Stock Unit Award Other +107 +2% 5.46K Nov 17, 2023 Ordinary Shares 107 Direct F1, F2, F5
transaction ALKS Employee Stock Option (Right to Buy) Other $35K +1.81K +2% $19.34 92.3K Nov 17, 2023 Ordinary Shares 1.81K $19.34 Direct F2, F6
transaction ALKS Restricted Stock Unit Award Other +221 +1.99% 11.3K Nov 17, 2023 Ordinary Shares 221 Direct F1, F2, F7
transaction ALKS Employee Stock Option (Right to Buy) Other $34.3K +1.39K +2% $24.59 71.2K Nov 17, 2023 Ordinary Shares 1.39K $24.59 Direct F2, F8
transaction ALKS Restricted Stock Unit Award Other +261 +1.99% 13.3K Nov 17, 2023 Ordinary Shares 261 Direct F1, F2, F9
transaction ALKS Employee Stock Option (Right to Buy) Other $34.3K +1.28K +2% $26.82 65.2K Nov 17, 2023 Ordinary Shares 1.28K $26.82 Direct F2, F10
transaction ALKS Restricted Stock Unit Award Other +319 +1.99% 16.3K Nov 17, 2023 Ordinary Shares 319 Direct F1, F2, F11
transaction ALKS Restricted Stock Unit Award Options Exercise -4.45K -33.33% 8.9K Feb 18, 2024 Ordinary Shares 4.45K Direct F1, F9
transaction ALKS Restricted Stock Unit Award Options Exercise -5.46K -100% 0 Feb 20, 2024 Ordinary Shares 5.46K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F3 These options are fully vested in accordance with their terms.
F4 Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.
F5 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.
F6 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.
F7 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.
F8 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.
F9 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.
F10 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.
F11 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

Remarks:

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney